2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Computer Vision, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5641 Alliance A042302: Phase III evaluation of fixed duration zanubrutinib plus sonrotoclax-based therapy compared to continuous zanubrutinib in previously untreated older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Jennifer R. Brown, MD, PhD, Jun Yin, PhD2, Danielle Brander, MD3, Shira Dinner, MD4, Joanna M Rhodes, MD, MSCE5, Allison Winter, MD6, Harry P. Erba, MD7, Selina Luger, MD, FRCPC8, Richard F. Little, MD9, Geoffrey L. Uy, MD10, Wendy Stock, MD11, Jennifer A. Woyach, MD12
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Duke University Medical Center, Durham, North Carolina, United States
4 Northwestern University, Chicago, Illinois, United States, University of Chicago, Chicago, Illinois, United States
5 Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Duke University Medical Center, Durham, North Carolina, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 National Cancer Institute, Bethesda, Maryland, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Background and Significance: Prior Alliance clinical trials have established the superiority of continuous ibrutinib therapy over chemoimmunotherapy in older adults with CLL. Whether continuous or time-limited targeted therapy is superior remains an open question, particularly in older adults. At present no clinical trials have addressed this question using a next generation BTK inhibitor with greater tolerability and reduced cardiac toxicity compared to ibrutinib. Additionally, non-randomized data suggest that minimal residual disease (MRD)-guided therapy may be superior to fixed duration therapy, but this issue has not been addressed in a randomized fashion.

Zanubrutinib is a second generation covalent BTK inhibitor that has been shown to improve progression-free survival (PFS) compared to ibrutinib in the relapsed setting, with significantly lower rates of atrial fibrillation. Sonrotoclax is a novel BCL-2 inhibitor that is approximately 10-fold more potent than venetoclax in vitro and retains activity against the most common resistance mutation, G101V. Zanubrutinib combined with sonrotoclax (ZS) has been evaluated in the frontline setting, in which the combination showed a 100% overall response rate (ORR), 60% complete remission (CR) rate and best undetectable MRD (uMRD) rate of 98% with a detection limit of one in 10-4. A registration trial comparing ZS to venetoclax obinutuzumab has completed accrual.

Study Design and Methods: Alliance A042302 (NCT07321652) is an NCI National Clinical Trials Network phase III study comparing continuous zanubrutinib to ZS, given either as a fixed duration regimen or a MRD-guided regimen with a single decision timepoint. Patients aged 65 years or older with previously untreated CLL/SLL are randomized 1:2 between continuous zanubrutinib given until progression or intolerance, or ZS given initially for 15 months. The randomization is stratified by age (65-75, or >75 years), by del17p status (positive or not detected), and by IGHV mutation status (mutated or unmutated). On the ZS arm, patients start with a three month lead-in of zanubrutinib prior to escalating sonrotoclax weekly over two months to 320 mg daily, continued thereafter with zanubrutinib. All patients undergo disease restaging at cycle 15 day 1 (C15D1), including peripheral blood MRD detection using Adaptive clonoSEQ®. Patients on the ZS arm who achieve uMRD at 10-5 sensitivity stop therapy, while those with detectable MRD (dMRD) at 10-5 sensitivity undergo second randomization to either an additional year of ZS therapy, or to discontinue therapy.

The two co-primary objectives are: (1) To compare the PFS between MRD-guided ZS therapy to continuous zanubrutinib as control (comparing patients on continuous zanubrutinib to those on ZS either with uMRD stopping at C15D28 or with dMRD randomized to receive an additional year of ZS); and (2) To determine the PFS comparing fixed duration ZS to continuous zanubrutinib as control (comparing patients on continuous zanubrutinib to those on ZS either with uMRD stopping at C15D28 or with dMRD randomized to stop at C15D28). Key secondary objectives include overall survival and PFS comparing patients randomized to stop vs those randomized to continue for an additional year of therapy, among patients with dMRD receiving ZS. This study uses a sequential multiple assignment randomized trial (SMART) design, in which all patients are randomized to a first-stage intervention and re-randomization to a second-stage intervention depends on an intermediate outcome, which in this case is MRD at C15D1. The study is powered for ZS superiority (estimated 5 year PFS 71% for continuous zanubrutinib and 83% for ZS including all patients) and 444 evaluable patients are required.

The study is currently active and enrollment has initiated.

Conclusions: Alliance A042302 is designed to address key questions in CLL therapy, including the comparative benefit of continuous vs time-limited therapy in older patients with CLL receiving a second generation covalent BTK inhibitor, and whether a simplified single timepoint MRD-guided approach can improve outcomes compared to fixed duration therapy.

Jennifer R. Brown, MD, PhD: iOnctura - Research Funding; BeOne (BeiGene) - Research Funding; Nagoon Therapeutics - Research Funding; Nurix Therapeutics - Research Funding; Loxo/Lilly - Research Funding; AbbVie - Consultancy (Includes expert testimony); Grifols Worldwide Operations - Consultancy (Includes expert testimony); Galapagos NV - Consultancy (Includes expert testimony); Loxo/Lilly - Consultancy (Includes expert testimony); Magnet Biomedicine - Consultancy (Includes expert testimony); Acerta/AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); InnoCare Pharma Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); BeOne (BeiGene) - Consultancy (Includes expert testimony); Nurix Therapeutics - Consultancy (Includes expert testimony); iOnctura - Consultancy (Includes expert testimony)